Browsing by Author "Ademisoye A.I."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Alteration of Early-Phase Piperaquine Disposition by Concurrent Administration of Clarithromycin in Healthy Volunteers
    (Advances in Pharmacology and Clinical Trials, 2024) Ademisoye A.I.
    Malaria and Helicobacter pylori infections are some of the most prevalent infectious diseases causing thousands of deaths worldwide. Concurrent infections can exacerbate co-morbidities or make worse the management of malaria. Drug-drug interactions arising from activities of CYP450 during concurrent management of the co-infections could worsen management challenges and therapeutic outcomes. Fifteen healthy volunteers were administered single oral dose of P-Alaxin© consisting piperaquine (960 mg) and dihydroartemisinin (240 mg). Following a five-month wash out period, clarithromycin (500 mg) was administered twice daily for five days. A single dose of P-Alaxin© was administered on the 3rd day. Blood samples were collected within 48 hours and analyzed for plasma levels of the administered drugs using RP-HPLC methods. The Tmax was 5.2±2.11 h vs 5.47±2.56 h and did not vary significantly p>0.05. However, Cmax and AUC0-48, of piperaquine when concurrently administered with clarithromycin increased significantly (179.41±56.35 ng/ml vs 478.99 ± 148.86 ng/ml; 37,644.56 ± 16.716.95 vs 104,098.47 ± 53.311.57 ng/ml*h respectively (p<0.05).quine during concurrent administration could be a pointer to major drug interactions that may manifest during full course of management of the concurrent infections. pharmacokinetic parameters in the early phase metabolism of piperaquine during concurrent administration cou
  • No Thumbnail Available
    Item
    Effect of Concurrent Administration of Herbs on the Pharmacokinetics of Drugs: A Review
    (Advances in Pharmacology and Clinical Trials, 2023) Ademisoye A.I.
    Herbal medicines are currently in high demand, and their popularity is steadily increasing as an alternative medicine. This is as a result of their perceived effectiveness, fewer side effects and relatively low cost. They are being used simultaneously with therapeutic drugs for the treatment and management of numerous medical conditions, but due to the complex mixture of bioactive constituents they are capable of affecting the pharmacokinetics and pharmacodynamics of conventional drugs when administered concurrently. Of serious concern is the concurrent consumption of herbal products and conventional drugs. Herb–drug inter-action (HDI) is the single most important clinical consequence of this practice. Using a structured assessment procedure, the evidence of HDI presents with varying degree of clinical significance. While the potential for HDI for a number of herbal products is inferred from non-human studies, certain HDIs are well established through human studies and documented case reports. This herb-drug interactions (HDIs) may lead to modifications in plasma drug levels resulting in therapeutic failure of the drug or, alternatively, it may cause drug-induced toxicity. The main routes proposed for HDIs include cytochrome P450 (CYP450)-mediated inhibition or induction and transport and flow proteins. In our review, some herbal medicines used for the treatment of various diseases were highlighted and case reports of their pharmacokinetics and pharmacodynamics herb-drug interactions were analyzed. Therefore, this review can be a quick reference tool for physicians, pharmacists and other healthcare professionals involved in therapy, and counseling towards appropriate use of drugs to maximize clinical outcomes.